

**BEFORE THE
MEDICAL BOARD OF CALIFORNIA
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA**

In the Matter of the Accusation filed)
Against:)
)
NICOLE POLIQUIN-WILLIAMS, M.D.)
P.O. Box 492027)
Los Angeles, CA 90049)
)
Physician's and Surgeon's)
Certificate No.: A-30419)
)
Respondent)
_____)

Case No.: 06-2007-187121

DECISION AND ORDER

The attached Stipulated Settlement and Disciplinary Order is hereby adopted by the Medical Board of California, Department of Consumer Affairs, as its Decision in this matter.

This Decision shall become effective at 5:00 p.m. on July 15, 2011

IT IS SO ORDERED June 15, 2011.

MEDICAL BOARD OF CALIFORNIA

By: 
HEDY CHANG
Chair

1 EDMUND G. BROWN JR.
Attorney General of California
2 ROBERT MCKIM BELL
Supervising Deputy Attorney General
3 COLLEEN M. MCGURRIN
Deputy Attorney General
4 State Bar No. 147250
300 South Spring Street, Suite 1702
5 Los Angeles, California 90013
Telephone: (213) 620-2511
6 Facsimile: (213) 897-9395
Attorneys for Complainant

7
8 **BEFORE THE**
MEDICAL BOARD OF CALIFORNIA
9 **DEPARTMENT OF CONSUMER AFFAIRS**
STATE OF CALIFORNIA

10 In the Matter of the Accusation Against:

11 **NICOLE POLIQUIN-WILLIAMS, M.D.**
12 **12720 Montana Avenue**
Los Angeles, CA 90049

13 **Physician's and Surgeon's Certificate No. A**
14 **30419**

15 Respondent.

Case No. 06-2007-187121

OAH No. 2010010251

STIPULATED SETTLEMENT AND
DISCIPLINARY ORDER

16 IT IS HEREBY STIPULATED AND AGREED by and between the parties to the above-
17 entitled proceedings that the following matters are true:

18 PARTIES

19 1. Linda K. Whitney (Complainant) is the current Executive Director of the Medical
20 Board of California (Board). At the time Accusation No. 06-2007-187121 was filed, Barbara
21 Johnston was the Executive Director of the Board and brought this action solely in her official
22 capacity. The Board is, and has been represented in this matter by Edmund G. Brown Jr.,
23 Attorney General of the State of California, by Colleen M. McGurrin, Deputy Attorney General.

24 2. Respondent, Nicole Poliquin-Williams, M.D. is represented in this proceeding by
25 attorney Raymond J. McMahon, whose address is 1851 East First Street, Suite 810, Santa Ana,
26 California 92705-4041.

27 3. On or about August 30, 1976, the Board issued Physician's and Surgeon's Certificate
28 No. A 30419 to Nicole Poliquin-Williams, M.D. The Physician's and Surgeon's Certificate was

1 in full force and effect at all times relevant to the charges brought in Accusation No. 06-2007-
2 187121, and will expire on August 31, 2010, unless renewed.

3 JURISDICTION

4 4. Accusation No. 06-2007-187121 was filed on November 25, 2009, before the Board,
5 Department of Consumer Affairs, and is currently pending against Respondent. The Accusation
6 and all other statutorily required documents were properly served on Respondent on November
7 25, 2009. Respondent timely filed her Notice of Defense on December 9, 2009, contesting the
8 Accusation. A copy of Accusation No. 06-2007-187121 is attached as Exhibit A and
9 incorporated herein by reference.

10 ADVISEMENT AND WAIVERS

11 5. Respondent has carefully read, fully discussed with counsel, and understands the
12 charges and allegations in Accusation No. 06-2007-187121. Respondent has also carefully read,
13 fully discussed with counsel, and understands the effects of this Stipulated Settlement and
14 Disciplinary Order on her Physician's and Surgeon's Certificate No. A 30419.

15 6. Respondent is fully aware of her legal rights in this matter, including the right to a
16 hearing on the charges and allegations in the Accusation; the right to be represented by counsel at
17 her own expense; the right to confront and cross-examine the witnesses against her; the right to
18 present evidence and to testify on her own behalf; the right to the issuance of subpoenas to
19 compel the attendance of witnesses and the production of documents; the right to reconsideration
20 and court review of an adverse decision; and all other rights accorded by the California
21 Administrative Procedure Act and other applicable laws.

22 7. Respondent voluntarily, knowingly, and intelligently waives and gives up each and
23 every right set forth above.

24 CULPABILITY

25 8. Respondent understands and agrees that the charges and allegations in Accusation
26 No. 06-2007-187121, if proven at a hearing, constitute cause for imposing discipline upon her
27 Physician's and Surgeon's Certificate.

28 9. Respondent admits that, at an administrative hearing, complainant could establish a

1 *prima facie* case with respect to the charges and allegations contained in Accusation No. 06-2007-
2 187121, a true and correct copy of which is attached hereto as Attachment "A," and hereby gives
3 up her right to contest those charges and allegations.

4 10. Respondent further agrees that her Physician's and Surgeon's Certificate No. A 30419
5 is subject to discipline and agrees to be bound by the Board's imposition of discipline as set forth
6 in the Disciplinary Order below.

7 CONTINGENCY

8 11. This stipulation shall be subject to approval by the Medical Board of California.
9 Respondent understands and agrees that counsel for Complainant and the staff of the Board may
10 communicate directly with the Board regarding this stipulation and settlement, without notice to
11 or participation by Respondent or her counsel. By signing the stipulation, Respondent
12 understands and agrees that she may not withdraw her agreement or seek to rescind the stipulation
13 prior to the time the Board considers and acts upon it. If the Board fails to adopt this stipulation
14 as its Decision and Order, the Stipulated Settlement and Disciplinary Order shall be of no force or
15 effect, except for this paragraph, it shall be inadmissible in any legal action between the parties,
16 and the Board shall not be disqualified from further action by having considered this matter.

17 ADDITIONAL PROVISIONS

18 12. This Stipulated Settlement and Disciplinary Order is intended by the parties herein to
19 be an integrated writing representing the complete, final and exclusive embodiment of the
20 agreements of the parties in the above-entitled matter.

21 13. The parties agree that facsimile copies of this Stipulated Settlement and Disciplinary
22 Order, including facsimile signatures of the parties, may be used in lieu of original documents and
23 signatures and, further, that facsimile copies and signatures shall have the same force and effect
24 as the originals.

25 14. In consideration of the foregoing admissions and stipulations, the parties agree the
26 Board may, without further notice to or opportunity to be heard by respondent, issue and enter the
27 following Disciplinary Order:

28 / / /

1 **DISCIPLINARY ORDER**

2 **A. PUBLIC REPRIMAND**

3 IT IS HEREBY ORDERED that Physician's and Surgeon's Certificate No. A 30419
4 issued to Respondent Nicole Poliquin-Williams, M.D. shall be and is hereby Publicly
5 Reprimanded pursuant to California Business and Professions Code section 2227, subdivision
6 (a)(4). This Public Reprimand is issued in connection with respondent's care and treatment of
7 patients X. B. and V. S.-B. as follows:

8 You failed to maintain adequate and accurate medical records for patients X. B. and
9 V.S.-B. as more fully described in Accusation No. 06-2007-187121.

10 **B. MEDICAL RECORDS KEEPING COURSE**

11 Within 60 calendar days of the effective date of this Decision, respondent shall enroll in a
12 course in medical record keeping, at respondent's expense, at the Physician Assessment and
13 Clinical Education Program (PACE) offered at the University of California - San Diego School of
14 Medicine ("Program"), or its equivalent, approved in advance by the Board or its designee.
15 Failure to successfully complete the course within 180 calendar days of the effective date of this
16 Decision shall constitute unprofessional conduct and grounds for further disciplinary action.

17 A medical record keeping course taken after the acts that gave rise to the charges in the
18 Accusation, but prior to the effective date of the Decision will be accepted towards the fulfillment
19 of this condition if the course would have been approved by the Board or its designee had the
20 course been taken after the effective date of this Decision.

21 Respondent shall submit a certification of successful completion to the Board or its
22 designee not later than 15 calendar days after successfully completing the course, or not later than
23 15 calendar days after the effective date of the Decision, whichever is later.

24 **C. PRESCRIBING PRACTICES COURSE**

25 Within 60 calendar days of the effective date of this Decision, respondent shall enroll in a
26 course in prescribing practices, at respondent's expense, approved in advance by the Division or
27 its designee. Failure to successfully complete the course within 180 calendar days of the effective
28 date of this Decision shall constitute unprofessional conduct and grounds for further disciplinary

1 action.

2 A prescribing practices course taken after the acts that gave rise to the charges in the
3 Accusation, but prior to the effective date of the Decision may, in the sole discretion of the
4 Division or its designee, be accepted towards the fulfillment of this condition if the course would
5 have been approved by the Division or its designee had the course been taken after the effective
6 date of this Decision.

7 Respondent shall submit a certification of successful completion to the Division or its
8 designee not later than 15 calendar days after successfully completing the course, or not later than
9 15 calendar days after the effective date of the Decision, whichever is later.

10 **D. PSYCHOPHARMACOLOGY COURSES**

11 Within 60 calendar days of the effective date of this Decision, respondent shall enroll in a
12 course equivalent to the "Psychopharmacology: A Masters Class" offered through Harvard
13 Medical School, or its equivalent, approved in advance by the Board or its designee, at
14 respondent's expense. Failure to successfully complete the course within 180 calendar days of
15 the effective date of this Decision shall constitute unprofessional conduct and grounds for further
16 disciplinary action.

17 A Psychopharmacology course taken after the acts that gave rise to the charges in the
18 Accusation, but prior to the effective date of the Decision will be accepted towards the fulfillment
19 of this condition if the course would have been approved by the Division or its designee had the
20 course been taken after the effective date of this Decision.

21 Respondent shall submit a certification of successful completion to the Division or its
22 designee not later than 15 calendar days after successfully completing the course, or not later than
23 15 calendar days after the effective date of the Decision, whichever is later.

24 **ACCEPTANCE**

25 I have carefully read this Stipulated Settlement and Disciplinary Order and, having the
26 benefit of counsel, enter into it freely, voluntarily, intelligently, and with full knowledge of its
27 force and effect on my Physician's and Surgeon's Certificate No. A 30419. I have fully discussed
28 the Stipulation, its contents, and its effects with my attorney, Raymond J. McMahon and enter

1 into this Stipulated Settlement and Disciplinary Order voluntarily, knowingly, and intelligently,
2 and agree to be bound by the Decision and Order of the Medical Board of California. I fully
3 understand that, after signing this stipulation, I may not withdraw from it, that it shall be
4 submitted to the Board for its consideration, and that the Board shall have a reasonable period of
5 time to consider and act on this stipulation after receiving it. By entering into this stipulation, I
6 fully understand that, upon formal acceptance by the Board, I shall be publically reprimanded by
7 the Board and shall be required to comply with all of the terms and conditions of the Disciplinary
8 Order set forth above. I also fully understand that any failure to comply with the terms and
9 conditions of the Disciplinary Order set forth above shall constitute unprofessional conduct and
10 will subject my Physician's and Surgeon's Certificate No. A 30419 to disciplinary action.

11
12 DATED: 6/17/10 Nicole Poliquin-Williams
13 NICOLE POLIQUIN-WILLIAMS, M.D.
14 Respondent

15 I have read and fully discussed with Respondent Nicole Poliquin-Williams, M.D. the terms
16 and conditions and other matters contained in the above Stipulated Settlement and Disciplinary
17 Order. I approve its form and content.

18
19 DATED: June 17, 2010 Raymond J. McMahon
20 Raymond J. McMahon
21 Attorney for Respondent

21 ///
22 ///
23 ///
24 ///
25 ///
26 ///
27 ///
28 ///

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28


ENDORSEMENT

The foregoing Stipulated Settlement and Disciplinary Order is hereby respectfully submitted for consideration by the Medical Board of California of the Department of Consumer Affairs.

Dated: 6/17/2010

Respectfully Submitted,

EDMUND G. BROWN JR.
Attorney General of California
ROBERT MCKIM BELL
Supervising Deputy Attorney General



COLLEEN M. MCGURRIN
Deputy Attorney General
Attorneys for Complainant

LA2009507912
50666034.doc

Exhibit A

Accusation No. 06-2007-187121

1 EDMUND G. BROWN JR.
Attorney General of California
2 COLLEEN M. MCGURRIN
Deputy Attorney General
3 State Bar No. 147250
300 South Spring Street, Suite 1702
4 Los Angeles, California 90013
Telephone: (213) 620-2511
5 Facsimile: (213) 897-9395
Attorneys for Complainant
6

7 **BEFORE THE**
8 **MEDICAL BOARD OF CALIFORNIA**
9 **DEPARTMENT OF CONSUMER AFFAIRS**
10 **STATE OF CALIFORNIA**

11 In the Matter of the Accusation Against:

Case No. 06-2007-187121

12 NICOLE POLIQUIN-WILLIAMS, M.D.

A C C U S A T I O N

13 12720 Montana Avenue
14 Los Angeles, California 90049

15 Physician's & Surgeon's Certificate A 30419,
Respondent.

16 Complainant alleges:

17 PARTIES

18 1. Barbara Johnston (Complainant) brings this Accusation solely in her official capacity
19 as the Executive Director of the Medical Board of California ("Board").

20 2. On or about August 30, 1976, the Board issued Physician's and Surgeon's Certificate
21 number A 30419 to Nicole Poliquin-Williams, M.D. ("Respondent"). That license has been in
22 full force and effect at all times relevant to the charges brought herein and will expire on August
23 31, 2010, unless renewed.

24 JURISDICTION

25 3. This Accusation is brought before the Board under the authority of the following
26 laws. All section references are to the Business and Professions Code unless otherwise indicated.

27 ///

28 ///

1 4. Section 2234 of the Code states, in pertinent part:

2 "The Division of Medical Quality¹ shall take action against any licensee who is charged
3 with unprofessional conduct. In addition to other provisions of this article, unprofessional
4 conduct includes, but is not limited to, the following:

5 "(a) Violating or attempting to violate, directly or indirectly, assisting in or abetting the
6 violation of, or conspiring to violate any provision of this chapter [Chapter 5, the Medical
7 Practice Act].

8 "(b) Gross negligence.

9 "(c) Repeated negligent acts. To be repeated, there must be two or more negligent acts or
10 omissions. An initial negligent act or omission followed by a separate and distinct departure from
11 the applicable standard of care shall constitute repeated negligent acts.

12 "(1) An initial negligent diagnosis followed by an act or omission medically appropriate for
13 that negligent diagnosis of the patient shall constitute a single negligent act.

14 "(2) When the standard of care requires a change in the diagnosis, act, or omission that
15 constitutes the negligent act described in paragraph (1), including, but not limited to, a
16 reevaluation of the diagnosis or a change in treatment, and the licensee's conduct departs from the
17 applicable standard of care, each departure constitutes a separate and distinct breach of the
18 standard of care.

19 "(d) . . . (f)."

20 5. Section 2227 of the Code states:

21 "(a) A licensee whose matter has been heard by an administrative law judge of the Medical
22 Quality Hearing Panel as designated in Section 11371 of the Government Code, or whose default
23 has been entered, and who is found guilty, or who has entered into a stipulation for disciplinary
24 action with the division, may, in accordance with the provisions of this chapter:

25 "(1) Have his or her license revoked upon order of the division.

26 ¹ California Business and Professions Code section 2002, as amended and effective January 1, 2008,
27 provides that, unless otherwise expressly provided, the term "board" as used in the State Medical Practice Act (Bus.
28 & Prof. Code § 2000, et seq.) means the "Medical Board of California," and references to the "Division of Medical
Quality" and "Division of Licensing" in the Act or any other provision of law shall be deemed to refer to the Board.

1 presumptive diagnosis of bipolar disorder³ based upon the patient's mood swings, agitation,
2 impulsivity and insomnia. Respondent, however, did not document a mental status examination
3 on this visit, nor is there evidence documented that the patient consistently demonstrated
4 symptoms of a bipolar disorder. Respondent also failed to document the patient's weight on this
5 visit, and prescribed Trileptal⁴ after discussing the drug's potential side effects with his parents.

6 9. On or about July 5, 2005, respondent again saw X.B., who was reportedly having
7 trouble taking the Trileptal and had thrown it up that morning. Respondent discontinued the
8 Trileptal and prescribed Depakote,⁵ in a form which could be mixed in soft foods to facilitate its
9 administration. Depakote requires regular laboratory monitoring of the patient's blood levels,
10 liver function, CBC and chemistry panels, and the dosage is initially calculated based upon the
11 patient's weight. Respondent also prescribed Adderall XR,⁶ an Attention-Deficit Hyperactivity
12 disorder (ADHD)⁷ medication. Respondent again failed to record X.B.'s weight on this visit, and
13 no mental status examination was documented.

14 10. On or about July 14, 2005, X.B. saw respondent again. At that time his sleep had
15 improved, but he was still experiencing behavioral problems. Besides failing to record the
16 patient's weight on this visit, respondent discontinued the Adderall XR, increased the Depakote,
17 and added a new prescription for Metadate CD.⁸

18 11. On or about July 19, 2005, respondent saw X.B. for another follow-up visit, and
19

20 ³ Bipolar disorder is a mood disorder that causes radical emotional changes and mood swings, from manic
highs to depressive lows.

21 ⁴ Trileptal is a trademark for the drug oxcarbazepine, an anticonvulsant generally used in the treatment of
partial seizures (any seizure due to a lesion in a specific, known area of the cerebral cortex).

22 ⁵ Depakote is a trademark for the drug divalproex sodium, and anticonvulsant drug, mood stabilizer, and
antimigraine agent which increases the level of gamma-aminobutyric acid in the brain, reducing seizure activity.

23 ⁶ Adderall is a brand-name for a pharmaceutical psychostimulant comprising mixed amphetamine salts.
24 This drug is used primarily to treat attention-deficit/hyperactivity disorder and narcolepsy, and is a Schedule II
controlled substance which has a high potential for abuse and addiction despite genuine medical use. Extended-
release (XR) pills are tablets or capsules formulated to dissolve slowly and release a drug over time.

25 ⁷ Attention-Deficit Hyperactivity disorder (ADHD) is generally considered to be a developmental disorder,
largely neurological in nature, affecting about 5% of the world's population. The disorder typically presents itself
26 during childhood, and is characterized by a persistent pattern of inattention and/or hyperactivity, as well as
forgetfulness, poor impulse control or impulsivity, and distractibility.

27 ⁸ Metadate CD is a brand name for a drug that contains methylphenidate (MPH) a central nervous system
28 (CNS) stimulant which has a calming effect on individuals who have ADHD by reducing their impulsive behavior,
and facilitating concentration on work and other tasks.

1 recorded his weigh at 40.5 pounds. His sleep had improved and his behavioral problems had
2 decreased somewhat, although he had struck one of his parents. Respondent increased the
3 Depakote and added a new prescription for Risperdal,⁹ however the dosage is unclear due to a
4 discrepancy in the record. The "Patient Medication Instruction" sheet on this date reflects a new
5 prescription for Risperdal liquid with a dosage of ¼ cc in juice at night, however, the "Note to
6 File", dated the same day, reflects a dosage of ½ cc or 0.5 mg.

7 12. Respondent saw X.B. again on or about August 8, 2005, who now weighed 45
8 pounds, and was doing very well with a few negative incidents. Respondent increased the
9 Metadate CD and Depakote dosages, but it is unclear if respondent decreased the patient's
10 Risperdal dose due to the above referenced discrepancy in the record.

11 13. On or about August 30, 2005, respondent saw the patient again. Respondent
12 modified X.B.'s medication regimen by adding new prescriptions for Lithium citrate¹⁰ and
13 Prozac,¹¹ decreased the Depakote dosage, however, it is unclear if the Metadate CD dose was
14 modified due to a discrepancy in the records.¹² On this visit, respondent failed to document any
15 information concerning X.B.'s mental, physical or emotional status other than his weight.

16 14. X.B. was next seen by respondent on or about October 11, 2005, and still weighed 45
17 pounds. He was having temper tantrums and was out of control between midday and the evening.
18 Respondent increased the Lithium and Metadate CD dosages.

19 15. On or about November 10, 2005, respondent first ordered X.B.'s blood levels to be
20 tested, however, no additional laboratory work, testing, or monitoring was ordered at this time.

21 16. On or about November 15, 2005, the patient's mood was stabilizing and he was
22 having very few tantrums. His weight was not recorded. Respondent increased the Lithium dose,
23 decreased the Depakote, and changed the timing of the Metadate CD dosage.

24 _____
25 ⁹ Risperdal is a trademark for the drug risperidone, an antipsychotic medication.

26 ¹⁰ Lithium is a soft, highly reactive metallic element whose carbonate form is used in psychopharmacology,
and is a drug which is used to treat manic depression (bipolar disorder).

27 ¹¹ Prozac is a trademark for the drug fluoxetine hydrochloride, and is an oral selective serotonin reuptake
inhibitor used for depression, obsessive-compulsive disorder, and bulimia nervosa.

28 ¹² The "Patient Medication Instruction" sheet on this date reflects a Metadate CD dose of 10 mg BID,
however, that day's "Note to File" reflects a dosage of 20 mg PO qAM.

1 17. On or about December 5, 2005, respondent increased the patient's Lithium dose, but
2 failed to document any information concerning X.B.'s mental, physical or emotional status on
3 this visit, including his weight.

4 18. On or about January 12, 2006, X.B. was reported to be "off track," had difficulty
5 going to bed, and had had a few tantrums. Respondent increased the Lithium and Depakote
6 dosages, discontinued the Metadate CD, and added a new prescription for Concerta,¹³ another
7 ADHD medication. X.B.'s weight, again, was not recorded.

8 19. On or about March 4, 2006, the patient was reportedly having great difficulty in the
9 mornings, and had been sick. His weight was again not recorded. Respondent added new
10 prescriptions for Seroquel¹⁴ and Ritalin.¹⁵ At this time, X.B.'s medication regimen included seven
11 (7) different medications: Concerta, Lithium, Depakote, Seroquel, Prozac, Risperdal and Ritalin.

12 20. On or about May 11, 2006, X.B. was having episodes of aggressive behavior and
13 appeared to be very anxious. His weight was again not recorded. Respondent increased the
14 Depakote and decreased the Concerta dosages.

15 21. On or about June 16, 2006, X.B. was reported to have improved self-esteem, but his
16 behavior remained somewhat erratic. His weight was, once again, not recorded. Respondent
17 increased the Concerta and decreased the Depakote.

18 22. Respondent next saw X.B. on or about July 13, 2006. At that time, he was having
19 difficulty in the mornings, becoming agitated and screaming, and refusing to take his
20 medications. Respondent again failed to record his weight, and increased the Depakote and
21 Lithium dosages, and decreased the Concerta.

22 23. On or about September 9, 2006, X.B. now weighed almost sixty (60) pounds. His
23 behavior was more often positive and he had been able to refrain from tantrums. Respondent
24 increased the Ritalin, Concerta and Risperdal dosages, but it is unclear if respondent decreased
25

26 ¹³ Concerta is another brand name for a once-daily extended release form of MPH, used to treat ADHD.

27 ¹⁴ Seroquel is a trade name for the drug quetiapine fumarate, an atypical antipsychotic medication.
According to the FDA boxed warning, this drug isn't approved for use in pediatric patients.

28 ¹⁵ Ritalin is a trademark for the central nervous system stimulant MPH.

1 the Lithium dosage at this time due to a discrepancy in the records.¹⁶

2 24. On or about November 17, 2006, X.B. was reported to have gained twenty (20)
3 pounds in the past few months; however, respondent did not record his weight or any other
4 information regarding his mental, emotional and physical condition on this visit. Respondent
5 increased the Depakote dose and added a new prescription for Tenex.¹⁷ It appears that
6 respondent may have modified the Seroquel regimen, but this is unclear due to a discrepancy in
7 the records.¹⁸ It is also unclear whether respondent discontinued the prescriptions for Risperdal,
8 Ritalin, Prozac and Concerta, as these medications are no longer reflected in the patient's medical
9 records.

10 25. On or about December 2006, X.B. was noted to be very hyperactive and impulsive.
11 His weight was again not recorded. Respondent added a new prescription for Geodon,¹⁹ restarted
12 the Adderall XR, increased the Depakote dosage, and modified his Seroquel regimen. The
13 Geodon was discontinued as it made him too sleepy.

14 26. On or about January 17, 2007, X.B. weighed sixty-six (66) pounds, and had been
15 hospitalized for a few days after becoming agitated. Respondent did not document any other
16 information concerning X.B.'s mental, emotional or physical condition on this visit, other than his
17 weight.

18 27. On or about April 12, 2007, X.B. was noted to be slightly hyper, and had a few bad
19 days at his new school. His weight was not recorded. Respondent restarted the Geodon,
20 increased the Adderall XR dosage, and added a new prescription for Cogentin.²⁰ Respondent

21
22 ¹⁶ The "Note to File" dated 7/13/05 reflects a Lithium dosage of 8mEq/cc 3ml PO TID. However, the
"Note to File", dated 9/9/06, reflects a Lithium dosage of 4cc PO BID.

23 ¹⁷ Tenex is a brand name for the drug guanfacine, a centrally acting antihypertensive medication used to
control high blood pressure. It was also prescribed off-label for the treatment of ADHD. In June 2007, the FDA
24 approved the use of guanfacine for ADHD treatment.

25 ¹⁸ The "Note to File" dated 9/9/06 reflects a Seroquel dosage of 25mg PO qd PRN. However, the "Note to
File", dated 11/17/06, notes Seroquel tabs iii PO qAM, tabs ii PO q12n & 4:30 and tabs i - ii PO PRN BID.

26 ¹⁹ Geodon is the brand name for the drug ziprasidone, and is an antipsychotic medication used as the
treatment of schizophrenia and has been approved for acute treatment of mania associated with bipolar disorder. It is
unclear when the Geodon was discontinued as this was the first visit in which the prescription was noted.

27 ²⁰ Cogentin is a trademark for an antiparkinson drug, benzotropine mesylate which inhibits cholinergic
excitatory pathways and restores balance of dopamine and acetylcholine in the central nervous system, thereby
28 decreasing excess salivation, rigidity, and tremors.

1 ordered X.B.'s blood levels to be checked for the second time.

2 28. On or about July 7, 2007, X.B. was again seen, however, respondent failed to
3 document any information concerning the patient's mental, emotional or physical condition.

4 29. X.B. was next seen by respondent on or about July 31, 2007, and weighed sixty-two
5 (62) pounds. He was having difficulty sleeping through the night and was agitated. Respondent
6 increased the Geodon and Tenex dosages.

7 30. On or about August 27, 2007, respondent saw X.B. for the last time. At that time,
8 X.B. was still having difficulties being disruptive at home, and becoming very angry and
9 attacking. His weight was not recorded. Respondent decreased the Geodon dosage and
10 discontinued the Tenex in the morning.

11 31. During the course of care and treatment of X.B., respondent failed to document the
12 rationale for changing, adjusting, discontinuing or adding more than one medication dosage at a
13 time, and never documented a formal mental status examination of this patient.

14 32. In respondents overall care and treatment of patient, X.B., the following acts and
15 omissions, collectively, constitute gross negligence:

- 16 a. adding, discontinuing, or adjusting more than two medication dosages at a time;
- 17 b. prescribing initial dosage of Depakote and Lithium without documentation of
18 having calculated the dosages based on the patient's weight and/or following laboratory
19 monitoring;
- 20 c. failure to order regular laboratory monitoring of the patient's blood, CBC,
21 liver, thyroid and chemistry panels;
- 22 d. failure to consistently monitor and document the patient's weight and vital
23 signs;
- 24 e. failure to consistently document the medical rationale for adding, discontinuing,
25 or adjusting medication doses;
- 26 f. failure to consistently gather and document information about the medications'
27 side effects and the patient's social, academic and community functioning; and
- 28 g. failure to document a mental status examination of this patient.

1 SECOND CAUSE FOR DISCIPLINE

2 (Gross Negligence – Patient V.S-B.)

3 33. Respondent is subject to disciplinary action under section Business and Professions
4 Code section 2234, subdivision (b), in that she was grossly negligent in her care and treatment of
5 patient V.S-B.. The circumstances are as follows:

6 34. On or about May 14, 2001, V.S-B., a then 36-year-old female patient, was seen by
7 respondent prior to her discharge from Las Encinas Hospital. At that time, respondent diagnosed
8 the patient with recurrent major depression. The patient was discharged on May 18, 2001, was
9 prescribed Effexor XR,²¹ Celexa,²² Neurontin,²³ Restoril,²⁴ and Ativan,²⁵ and was given a follow
10 up appointment with respondent.

11 35. On or about May 24, 2001, the patient presented to respondent's office. During this
12 time, and through July 2006, respondent principally saw the patient for the management of her
13 medications. At this visit, the patient was depressed and anxious. Respondent increased the
14 Effexor and Neurontin dosages.

15 36. On or about June 14, 2001, respondent next saw V.S-B. who complained of increased
16 anxiety, anger, irritability, and decreased patience. Respondent increased the Celexa and
17 Neurontin dosages.

18 37. On or about August 23, 2001, the patient saw respondent for a follow up visit and
19 complained of being overwhelmed. Respondent started the patient on Seroquel, and decreased the
20 Neurontin dose. Respondent ordered a chemistry, CBC, and thyroid panel which were all
21 reported to be normal.

22 ²¹ Effexor is a trademark for the drug venlafaxine hydrochloride an antidepressant, anxiolytic, which
23 inhibits neuronal serotonin and norepinephrine reuptake and slightly inhibits dopamine reuptake.

24 ²² Celexa is a trademark for the drug citalopram hydrobromide, an antidepressant which is thought to
25 potentiate serotonergic (containing or activated by serotonin) activity in the central nervous system by inhibiting
26 neuronal uptake of serotonin (a chemical produced by the brain that functions as a neurotransmitter).

27 ²³ Neurontin is a trademark for the drug gabapentin, an anticonvulsant which appear to stabilize cell
28 membranes by altering sodium, calcium and potassium transport, thereby decreasing excitability and suppressing
seizure discharge or focus.

²⁴ Restoril is a trademark for the drug temazepam a sedative-hypnotic which depresses the central nervous
system at the limbic, thalamic, and hypothalamic levels.

²⁵ Ativan is a trademark for the drug lorazepam an antianxiety agent which is thought to depress the central
nervous system at the limbic system and disrupt neurotransmission in reticular (net like) activating system.

1 38. On or about April 4, 2002, the patient saw respondent and complained of mood
2 swings and racing thoughts. Respondent decreased the Celexa dose, added a new prescription for
3 Lithobid.²⁶

4 39. V.S-B. saw respondent again on or about June 11, 2002, and complained of increased
5 tension. At that time, respondent increased the Lithobid dose, added a new prescription for
6 Prozac, and discontinued the Celexa.

7 40. On or about July 11, 2002, respondent next saw V.S-B. who complained of being
8 irritable all the time. Respondent diagnosed the patient with Bipolar disorder, mixed.
9 Respondent, however, did not document a mental status examination on this date, nor do the
10 records reflect that the patient consistently demonstrated specific and discrete bipolar symptoms,
11 or that respondent ruled out any other medical conditions or medication side effects that may
12 mimic bipolar symptoms. Respondent decreased the dosage of Effexor, discontinued the
13 Neurontin, and added a new prescription for Risperdal, a bipolar medication, to the patient's
14 medication regimen.

15 41. On or about August 1, 2002, respondent saw the patient again. At that time,
16 respondent increased the Prozac, gave the patient a sample of the drug BuSpar,²⁷ and added a
17 prescription for Xanax.²⁸

18 42. On or about December 3, 2002, the patient's Lithium levels were reported to be 1.0.
19 In the December 5, 2002 Note to File, however, respondent recorded the level as 0.7 .

20 43. On or about February 6, 2003, V.S-B. saw respondent again. At that time, she had
21 increased lability and was experiencing side effects from the Lithobid. Respondent decreased the
22 Lithobid, discontinued the Prozac, and added new prescriptions for Paxil,²⁹ Abilify,³⁰ and

23 ²⁶ Lithobid is a trademark for the antimanic drug lithium carbonate which is thought to disrupt sodium
24 exchange and transport in nerves and muscles and control reuptake of neurotransmitters.

25 ²⁷ BuSpar is a trademark for the drug buspirone hydrochloride, an anti-anxiety drug which is thought to
26 bind to serotonin and dopamine receptors in the central nervous system, increasing dopamine metabolism and
27 impulse formation. It is also thought to inhibit neuronal firing and reduce serotonin turnover.

28 ²⁸ Xanax is a trademark for the drug alprazolam, an anxiolytic (a drug that relieves anxiety) which is
29 thought to act at the limbic, thalamic and hypothalamic levels of the central nervous system to produce sedative,
30 anxiolytic, skeletal muscle relaxant, and anticonvulsant effects.

²⁹ Paxil is the brand name for the drug paroxetine, a selective serotonin (a hormone and neurotransmitter)
reuptake inhibitor used as an oral antidepressant.

1 Trileptal.

2 44. On or about March 2003, respondent ordered the patient's liver function and thyroid
3 panels tested. Thereafter, no further liver, thyroid, lipid or chemistry panels were ordered until
4 February 2005.

5 45. Respondent saw V.S-B. again on or about June 3, 2003. At that time, the patient
6 complained of headaches, explosive behavior, and diarrhea secondary to the Lithobid.

7 Respondent increased the Trileptal and BuSpar dosages, and added a new prescription of
8 Topamax.³¹ The patient's medication regiment now included eight (8) different psychotropic
9 medications: Topamax, Lithobid, Trileptal, Paxil, BuSpar, Xanax, Abilify and Seroquel.

10 46. On or about August 7, 2003, respondent saw the patient again. On this date,
11 respondent discontinued the Topamax, increased the Paxil, and decreased the Abilify.

12 47. Respondent next saw the patient on or about October 2, 2003, who was more stable
13 and had few complaints. Respondent discontinued the Lithobid and Seroquel, decreased the
14 Trileptal, BuSpar and Paxil, and added a new prescription for Eskalith CR.³²

15 48. On or about March 4, 2004, the patient was again seen by respondent, and was doing
16 well. Respondent decreased the Abilify dosage, discontinued the Xanax, and added a new
17 prescription for Klonopin.³³

18 49. On or about May 6, 2004, V.S-B. next saw respondent, and complained of being
19 sleepy during the day and the patient was objectively over sedated. Respondent increased the
20 Abilify, discontinued the Paxil CR and the regular Klopopin prescriptions, added a new
21 prescription for Wellbutrin XL,³⁴ and prescribed Klopopin wafers.

22 50. On or about May 24, 2004, respondent saw the patient again who was very depressed,
23

24 ³⁰ Abilify is the brand name for the drug Aripiprazole an antipsychotic medication for the treatment of
25 schizophrenia. It recently received approval from the Federal Drug Administration for the treatment of acute manic
26 and mixed episodes associated with bipolar disorder.

26 ³¹ Topamax is a brand name for Topiramate an anticonvulsant drug which is used to treat epilepsy and
27 sometimes as an antidepressant.

27 ³² Eskalith CR is a trademark for a drug containing lithium carbonate, a medication used to treat bipolar
28 affective disorders.

³³ Klonopin is a trademark for the drug clonazepam, an anticonvulsant.

³⁴ Wellbutrin XL is a trademark for the drug bupropion hydrochloride, used to treat depression.

1 unable to concentrate, and complained of diarrhea. Respondent increased the Trileptal and
2 Wellbutrin dosages, discontinued the Eskalith, and restarted the Seroquel.

3 51. V.S-B. saw respondent again on or about August 19, 2004, and reported that her
4 mood was fairly stable. Respondent increased the Abilify, and added a new prescription for
5 Lexapro.³⁵

6 52. The patient was next seen by respondent on or about January 31, 2005. At that time,
7 the patient complained of having panic attacks, worrying all the time, and was seeking Xanax.
8 Respondent discontinued the Wellbutrin and added a new prescription for Cymbalta.³⁶

9 53. On or about February 17, 2005, respondent's partner, Joseph Haraszti, M.D., ordered
10 laboratory monitoring of the patient's CBC, thyroid and Lithium levels, although these results
11 were not reported until September 16, 2005.

12 54. On or about May 16, 2005, the patient was next seen by respondent who noted that
13 the patient's mood was still unstable. Respondent increased the Lithium dose, and discontinued
14 the Wellbutrin, however, there is a discrepancy in the record as this medication was previously
15 discontinued several months earlier on January 31, 2005.

16 55. V.S-B. was next seen by respondent on or about August 2, 2005. At that time, the
17 patient was stressed and experiencing anxiety attacks. Respondent increased the Seroquel,
18 Trileptal and Cymbalta dosages.

19 56. V.S-B. saw respondent again on or about November 15, 2005, and complained of
20 twitching. The patient was feeling much better with her anxiety under control, but was irritable
21 all the time. Respondent increased the Cymbalta, decreased the Abilify (which respondent
22 believed might be responsible for the twitching), and added a new prescription for Lunestra.³⁷

23 57. On or about May 11, 2006, respondent saw the patient again who was doing better
24 and her mood was stable. Respondent discontinued the Lunestra and added a new prescription

25 _____
26 ³⁵ Lexapro is a trademark for the drug escitalopram oxalate, an antidepressant which prevents serotonin
27 reuptake by the central nervous system neurons, making more serotonin available in the brain and thereby relieving
28 depression.

³⁶ Cymbalta is a trademark for the drug duloxetine, an antidepressant.

³⁷ Lunestra is a trademark for the drug eszopiclone, a hypnotic which is generally prescribed for insomnia.

1 for Ambien.³⁸

2 58. On or about August 9, 2006, respondent began psychotherapy sessions with the
3 patient.

4 59. On or about August 24, 2006, the patient was noted to be taking the following
5 medications: Abilify, Seroquel, Lunestra, Ambien, Cymbalta, Lithium, Klonopin and Trileptal,
6 however, there is another discrepancy in the record as respondent recorded that she discontinued
7 the Lunestra several months earlier on May 11, 2006.

8 60. On or about September 29, 2006, respondent saw the patient again who was feeling
9 tired and angry. Respondent noted the patient's current medications as: Lithium, Lunestra,
10 Cymbalta, BuSpar, Abilify, Risperdal and Xanax.

11 61. Respondent saw the patient again several times during October 2006 and made no
12 changes to her medications.

13 62. On or about November 10, 2006, respondent saw V.S-B. who was depressed, feeling
14 down and tired. Respondent noted the patient's current medications as: Lithium, Klonopin,
15 BuSpar, Abilify, Cymbalta, Lunestra and Xanax, however, there is another discrepancy in the
16 record as Klonopin was not listed as one of the patient's current medications as of September 29,
17 2006.

18 63. Respondent continued treating the patient into 2007. On or about March 25, 2007,
19 respondent decreased the dosages of Lithium and BuSpar, discontinued the Risperdal, and added
20 another prescription for Topamax. There is, however, another discrepancy in the record as
21 Risperal was not listed as one of the patient's current medications as of November 10, 2006.

22 64. On or about May 16, 2007, respondent saw the patient again, who complained of
23 obsessive thoughts. Respondent increased the Lexapro dose, however, there is a discrepancy in
24 the record as this medication is not listed as one of the patient's current medications as of
25 November 10, 2006 nor August 28, 2006.

26 65. On or about June 14, 2007, V.S-B. was noted to be taking BuSpar, Cymbalta,

27 ³⁸ Ambien is a trademark for the drug zolpidem tartrate, a sedative-hypnotic generally prescribed for
28 insomnia.

1 Topamax, Abilify, Neurontin,³⁹ Wellbutrin XL, and Trazodone.⁴⁰ On or about June 16, 2007,
2 respondent increased the Neurontin and Lunestra doses, decreased the Wellbutrin and Cymbalta,
3 and added a new prescription for Robaxin.⁴¹

4 66. On or about June 20, 2007, respondent saw the patient who complained of depression
5 and anxiety. Respondent discontinued the Neurontin which the patient did not feel was helping.

6 67. V.S-B. saw respondent again on or about June 27, 2007, and complained of being
7 anxious and depressed with suicidal ideations, but no plan. Respondent increased the dosages of
8 Cymbalta, Topamax, and BuSpar, and lists Ritalin as another one of the patient's medications,
9 however, this medication was not previously listed as one of the patient's medications.

10 Respondent also discontinued the Neurontin, however, there is a discrepancy in the record as this
11 medication was noted to be discontinued on June 20, 2007.

12 68. On or about June 28, 2007, respondent added a new prescription for Lamictal⁴² to the
13 patient's medication regimen.

14 69. On or about July 3, 2007, V.S-B. saw respondent again and complained of being very
15 depressed with suicidal ideations, indicating she would "do it" if it was the only way out, and
16 admitted using Klonopin to decrease her anxiety. Respondent and the patient entered into a
17 suicide contract.⁴³ The following day, on or about July 4, 2007, the patient took an overdose of
18 Klonopin.

19 70. On or about July 9, 2007, respondent saw V.S-B. who complained of feeling angry
20 and was having cravings to escape reality. Respondent did not document any inquiry into
21 whether the patient was having any suicidal thoughts or ideations five days after the overdose.

22 ³⁹ Neurontin is a trademark for the drug gabapentin, an anticonvulsant that appears to stabilize cell
23 membranes by altering cation (sodium, calcium and potassium) transport, thereby decreasing excitability and
suppressing seizure discharge or focus.

24 ⁴⁰ Trazodone is an antidepressant used as the hydrochloride salt to treat major depressive episodes.

25 ⁴¹ Robaxin is a trademark for the drug methocarbamol, a skeletal muscle relaxant that is thought to depress
the central perception of pain without directly relaxing skeletal muscles or directly affecting motor endplate or motor
nerves.

26 ⁴² Lamictal is a trademark for the drug lamotrigine, an anticonvulsant which is thought to block sodium
channel membranes, which in turn inhibits release of the neurotransmitters glutamate and aspartate in the brain.

27 ⁴³ The Suicide Contract states that the patient "will call Dr. Poliquin before I take any pills to kill myself. I
28 will call if there is a crisis which makes me feel suicidal or have loss of control" and Dr. Poliquin agreed that she
"will be open to receiving [the patient's] call 24/7 until the situation has stabilized."

1 Respondent gave the patient Tenex, Neurontin and Seroquel.

2 71. Respondent saw the patient again on or about August 1, 2007, who felt less depressed
3 and moody. Respondent discontinued the Tenex and Seroquel, and noted the patient's current
4 medication regimen as: Cymbalta, Lunesta, BuSpar, Topamax, Wellbutrin, Neurontin, Lamictal
5 and Naltrexone.⁴⁴

6 72. On or about August 8, 2007, respondent saw V.S-B. who reported improvement.
7 Respondent decreased the Naltrexone, Cymbalta and BuSpar dosages.

8 73. Respondent last saw the patient on or about August 27, 2007, who was feeling
9 depressed and anxious, but wanted to decrease all of her medications. Respondent discontinued
10 the Cymbalta, Topamax and Naltrexone, but continued the patient's regimen of Lamictal,
11 Wellbutrin and BuSpar.

12 74. During the course of care and treatment of V.S-B., respondent failed to consistently
13 document the rationale for adding, changing, discontinuing or adjusting more than one
14 medication dosage at a time and never documented a mental status examination of this patient.

15 75. In respondents overall care and treatment of patient, V.S-B., the following acts and
16 omissions, collectively, constitute gross negligence:

- 17 a. diagnosing the patient with Bipolar disorder instead of a depressive disorder
18 without documented evidence that the patient consistently demonstrated bipolar disorder
19 symptoms;
- 20 b. adding, discontinuing, or adjusting more than two medication dosages at a time;
- 21 c. failure to order regular laboratory monitoring of the patient's blood, CBC, liver,
22 thyroid and chemistry panels;
- 23 d. failure to consistently document the rationale for adding, discontinuing or
24 adjusting medication doses;
- 25 e. failure to consistently gather and document information about the effects and/or
26 side effects of the medications prescribed; and

27 _____
28 ⁴⁴ Naltrexone is an opioid antagonist used as the hydrochloride salt in treatment of opioid or alcohol abuse.

1 f. failure to document a mental status examination of this patient.

2 **THIRD CAUSE FOR DISCIPLINE**

3 (Repeated Negligent Acts – Patient X.B.)

4 76. Respondent is subject to disciplinary action under section Business and Professions
5 Code section 2234, subdivision (c) in that respondent committed repeated negligent acts in her
6 care and treatment of patient, X.B. The circumstances are as follows:

7 77. Paragraphs 8 through 32 inclusive are incorporated herein by reference as if fully set
8 forth.

9 78. Respondent was further negligent in her care and treatment of X.B., in that she
10 diagnosed the patient with bipolar disorder with no documented evidence that the patient
11 consistently demonstrated bipolar disorder symptoms.

12 **FOURTH CAUSE FOR DISCIPLINE**

13 (Repeated Negligent Acts – Patient V.S-B.)

14 79. Respondent is subject to disciplinary action under section Business and Professions
15 Code section 2234, subdivision (c) in that respondent committed repeated negligent acts in her
16 care and treatment of patient, V.S-B. The circumstances are as follows:

17 80. Paragraphs 34 through 75 inclusive are incorporated herein by reference as if fully set
18 forth.

19 **FIFTH CAUSE FOR DISCIPLINE**

20 (Failure to Maintain Adequate and Accurate Medical Records)

21 81. Respondent is subject to disciplinary action under section Business and Professions
22 Code section 2266 in that respondent failed to maintain adequate and accurate medical records in
23 her care and treatment of patients, X.B. and V.S-B. The circumstances are as follows:

24 82. Paragraphs 8 through 32, and 34 through 75, inclusive, are incorporated herein by
25 reference as if fully set forth.

26 **PRAYER**

27 **WHEREFORE**, Complainant requests that a hearing be held on the matters herein alleged,
28 and that following the hearing, the Medical Board of California issue a decision:

1 1. Revoking or suspending Physician's and Surgeon's Certificate Number A 30419,
2 issued to Nicole Poliquin-Williams, M.D.


3 2. Revoking, suspending or denying approval of respondent's authority to supervise
4 physician assistants, pursuant to section 3527 of the Code;

5 3. Ordering respondent to pay the Medical Board of California the costs of probation
6 monitoring, if placed on probation; and

7 4. Taking such other and further action as deemed necessary and proper.

8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

DATED: November 25, 2009


BARBARA JOHNSTON
Executive Director
Medical Board of California
Department of Consumer Affairs
State of California
Complainant

LA2009507912
50533359.docx